Hormonal Modulation in the Treatment of Breast Cancer

被引：8
作者：
Adelson, Kerin [1 ]
Germain, Doris [2 ]
Raptis, George [1 ]
Biran, Noa [3 ]
机构：
[1] Mt Sinai Sch Med, Div Hematol & Med Oncol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY 10029 USA
[3] Mt Sinai Med Ctr, Samuel Bronfman Dept Med, New York, NY 10029 USA
来源：
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2011年 / 40卷 / 03期
关键词：
Hormonal modulation; Breast cancer; Aromatase inhibitors; Ovarian suppression; GnRH agonist; Antiestrogens; SERM; SERD; SURGICAL ADJUVANT BREAST; SELECTIVE AROMATASE INHIBITOR; ACETATE V TAMOXIFEN; FIRST-LINE THERAPY; PHASE-III TRIAL; POSTMENOPAUSAL WOMEN; MEGESTROL-ACETATE; RANDOMIZED-TRIAL; PREMENOPAUSAL WOMEN; BOWEL PROJECT;
D O I：
10.1016/j.ecl.2011.05.011
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This article explores the history of endocrine therapy for the treatment of breast cancer, the clinical evidence behind the current standards of care, and controversies that may change these standards in the future.
引用
收藏
页码：519 / +
页数：15
相关论文
共 64 条
[1]  
Abe O, 2005, LANCET, V366, P2087, DOI 10.1016/s0140-6736(05)66544-0
[2]  
Altekruse S F., SEER CANC STAT REV 1
[3]  
[Anonymous], 1996, Lancet, V348, P1189
[4]  
[Anonymous], CANC FACTS FIG
[5]  
ANSFIELD FJ, 1974, CANCER, V33, P907, DOI 10.1002/1097-0142(197404)33:4<907::AID-CNCR2820330403>3.0.CO
[6]  
2-Y
[7]  
Baum M, 2002, LANCET, V359, P2131
[8]  
Beatson G.T., 1896, LANCET, V2, P162
[9]  
BLISS JM, 2009, 32 ANN SAN ANT BREAS
[10]   Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate [J].
Buzdar, A ;
Douma, J ;
Davidson, N ;
Elledge, R ;
Morgan, M ;
Smith, R ;
Porter, L ;
Nabholtz, J ;
Xiang, X ;
Brady, C .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3357-3366
1234567